Daily controllers are medicines taken every day to lower persistent agitation, while as-needed medicines are taken only during a crisis. For Alzheimer's behavioral symptoms, daily control suits ongoing agitation and as-needed sedation is generally discouraged for routine use. Agitation here means restlessness, shouting, pacing, or aggression linked to dementia due to Alzheimer's disease. A daily controller builds a steady effect over weeks, while an as-needed drug acts briefly and can impair thinking and balance.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- When does a daily medicine fit?
- What daily options does the evidence support?
- How is the approved daily drug taken?
- Why are as-needed sedatives discouraged?
- How do clinicians limit risk when medicine is used?
When does a daily medicine fit?
A daily medicine fits when agitation happens often and disrupts care, sleep, or safety. It aims to reduce frequency and intensity, not to sedate a person after an outburst.
The National Institute on Aging advises caregivers to try calm reassurance, listening, routine, and removal of triggers first. The same guidance notes medications can treat some behavioral symptoms and families should ask a clinician whether medicine is needed.
What daily options does the evidence support?
The U.S. Food and Drug Administration granted supplemental approval to Rexulti brexpiprazole for agitation associated with dementia due to Alzheimer's disease, the first FDA-approved option for that indication, based on two 12-week randomized placebo-controlled trials, according to the FDA approval notice.
Approval means regulators reviewed benefit and risk for this specific use. In the CitAD randomized trial of 186 Alzheimer's patients with agitation, daily citalopram 30 mg produced moderate or marked improvement in 40% versus 26% on placebo. That result supports daily SSRI use for persistent agitation when a clinician selects it.
How is the approved daily drug taken?
Rexulti's FDA label defines it as a daily controller, not an as-needed treatment, with dosing of 0.5 mg once daily Days 1-7, 1 mg Days 8-14, target 2 mg daily, maximum 3 mg daily, as listed in the current DailyMed label. A person takes it each day whether agitation is present that morning or not.
Daily antidepressant controllers also need caution in older adults. Citalopram improved agitation but prolonged QTc by about 18 ms at week 3 versus placebo, so treatment requires ECG and dose caution.
Why are as-needed sedatives discouraged?
As-needed lorazepam or alprazolam may seem practical before visits, baths, or bedtime. The 2023 American Geriatrics Society Beers Criteria recommend avoiding all benzodiazepines in older adults because they cause cognitive impairment, delirium, falls, fractures, and crashes, as summarized by the National Committee for Quality Assurance in its deprescribing report.
All antipsychotics also carry an FDA boxed warning because elderly patients with dementia-related psychosis face increased mortality, about 1.6-1.7 times placebo risk, about 4.5% versus 2.6% over 10 weeks in pooled trials. That risk is one reason quick sedation is not a simple tradeoff.
How do clinicians limit risk when medicine is used?
Clinicians reserve scheduled antipsychotics for severe, dangerous agitation or psychosis after non-drug measures fail. They use the lowest effective dose for the shortest time with planned taper and monitoring for stroke, metabolic effects, and falls. Families can support safer use with a short checklist:.
- Track date, trigger, behavior, and what calmed the person.
- Ask about ECG, fall risk, stroke risk, and drug interactions.
- Review dose, duration, taper plan, and follow-up at each visit.
- Report excess sleepiness, stiffness, fever, fainting, or new confusion promptly.
